Conjugation of a peptide to an antibody engineered with free cysteines dramatically improves half-life and activity

References

• Kreymann B, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300–11. doi:https://doi.org/10.1016/S0140-6736(87)91194-9.
   PubMed Web of Science ®Google Scholar
• Gutniak M, Ørkov C, Holst JJ, Ahrén B, Efendić S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326(20):1316–22. doi:https://doi.org/10.1056/NEJM199205143262003.
   PubMed Web of Science ®Google Scholar
• Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38(4):665–73. doi:https://doi.org/10.1007/BF01316798.
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515–20. doi:https://doi.org/10.1172/JCI990.
   PubMed Web of Science ®Google Scholar
• Schulman JL, Carleton JL, Whitney G, Whitehorn JC. Effect of glucagon on food intake and body weight in man. J Appl Physiol. 1957;11(3):419–21. doi:https://doi.org/10.1152/jappl.1957.11.3.419.
   PubMed Web of Science ®Google Scholar
• Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003;88(10):4696–701. doi:https://doi.org/10.1210/jc.2003-030421.
   PubMed Web of Science ®Google Scholar
• Bagger JI, Holst JJ, Hartmann B, Andersen B, Knop FK, Vilsbøll T. Effect of oxyntomodulin, glucagon, GLP-1, and combined glucagon +GLP-1 infusion on food intake, appetite, and resting energy expenditure. J Clin Endocrinol Metab. 2015;100(12):4541–52. doi:https://doi.org/10.1210/jc.2015-2335.
   PubMed Web of Science ®Google Scholar
• Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005;54(8):2390–95. doi:https://doi.org/10.2337/diabetes.54.8.2390.
   PubMed Web of Science ®Google Scholar
• Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond). 2006;30(12):1729–36. doi:https://doi.org/10.1038/sj.ijo.0803344.
   PubMed Web of Science ®Google Scholar
• Tan TM, Field BCT, McCullough KA, Troke RC, Chambers ES, Salem V, Gonzalez Maffe J, Baynes KCR, De Silva A, Viardot A. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62(4):1131–38. doi:https://doi.org/10.2337/db12-0797.
   PubMed Web of Science ®Google Scholar
• Chakravarthy M, Parsons S, Lassman ME, Butterfield K, Lee AYH, Chen Y, Previs S, Spond J, Yang S, Bock C. Effects of 13-hour hyperglucagonemia on energy expenditure and hepatic glucose production in humans. Diabetes. 2017;66(1):36–44. doi:https://doi.org/10.2337/db16-0746.
   PubMed Web of Science ®Google Scholar
• Shankar SS, Shankar RR, Mixson LA, Miller DL, Pramanik B, O’Dowd AK, Williams DM, Frederick CB, Beals CR, Stoch SA. Native oxyntomodulin has significant glucoregulatory effects independent of weight loss in obese humans with and without type 2 diabetes. Diabetes. 2018;67(6):1105–12. doi:https://doi.org/10.2337/db17-1331.
   PubMed Web of Science ®Google Scholar
• Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem. 2003;278(25):22418–23. doi:https://doi.org/10.1074/jbc.M212355200.
   PubMed Web of Science ®Google Scholar
• Liu Y-L, Ford HE, Druce MR, Minnion JS, Field BCT, Shillito JC, Baxter J, Murphy KG, Ghatei MA, Bloom SR. Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. Int J Obes (Lond). 2010;34(12):1715–25. doi:https://doi.org/10.1038/ijo.2010.110.
   PubMed Web of Science ®Google Scholar
• Kervran A, Dubrasquet M, Blache P, Martinez J, Bataille D. Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney. Regul Pept. 1990;31(1):41–52. doi:https://doi.org/10.1016/0167-0115(90)90194-2.
   PubMedGoogle Scholar
• Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson‐Löfmark R, Naylor J, Rossi A, Bednarek MA, et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab. 2016;18(12):1176–90. doi:https://doi.org/10.1111/dom.12735.
   PubMed Web of Science ®Google Scholar
• Evers A, Haack T, Lorenz M, Bossart M, Elvert R, Henkel B, Stengelin S, Kurz M, Glien M, Dudda A. Design of novel exendin-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. J Med Chem. 2017;60(10):4293–303. doi:https://doi.org/10.1021/acs.jmedchem.7b00174.
   PubMed Web of Science ®Google Scholar
• Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258–66. doi:https://doi.org/10.2337/db09-0278.
   PubMed Web of Science ®Google Scholar
• Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749–57. doi:https://doi.org/10.1038/nchembio.209.
   PubMed Web of Science ®Google Scholar
• Boccara F, Dent R, Ruilope L, Valensi P. Practical considerations for the use of subcutaneous treatment in the management of dyslipidaemia. Adv Ther. 2017;34(8):1876–96. doi:https://doi.org/10.1007/s12325-017-0586-8.
   PubMed Web of Science ®Google Scholar
• Doppalapudi VR, Tryder N, Li L, Aja T, Griffith D, Liao -F-F, Roxas G, Ramprasad MP, Bradshaw C, Barbas CF. Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies. Bioorg Med Chem Lett. 2007;17(2):501–06. doi:https://doi.org/10.1016/j.bmcl.2006.10.009.
   PubMed Web of Science ®Google Scholar
• Murphy RE, Kinhikar AG, Shields MJ, Del Rosario J, Preston R, Levin N, Ward GH. Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples. J Pharm Biomed Anal. 2010;53(3):221–27. doi:https://doi.org/10.1016/j.jpba.2010.04.028.
   PubMed Web of Science ®Google Scholar
• Wang Y, Du J, Zou H, Liu Y, Zhang Y, Gonzalez J, Chao E, Lu L, Yang P, Parker H. Multifunctional antibody agonists targeting glucagon-like peptide-1, glucagon, and glucose-dependent insulinotropic polypeptide receptors. Angew Chem Int Ed Engl. 2016;55(40):12475–78. doi:https://doi.org/10.1002/anie.201606321.
   PubMed Web of Science ®Google Scholar
• Vauquelin G, Charlton SJ. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol. 2013;168(8):1771–85. doi:https://doi.org/10.1111/bph.12106.
   PubMed Web of Science ®Google Scholar
• Angal S, King DJ, Bodmer MW, Turner A, Lawson ADG, Roberts G, Pedley B, Adair JR. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993;30(1):105–08. doi:https://doi.org/10.1016/0161-5890(93)90432-B.
   PubMed Web of Science ®Google Scholar
• Alegre M-L, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA. A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 1994;57(11):1537–43. doi:https://doi.org/10.1097/00007890-199457110-00001.
   PubMed Web of Science ®Google Scholar
• Santoprete A, Capitò E, Carrington PE, Pocai A, Finotto M, Langella A, Ingallinella P, Zytko K, Bufali S, Cianetti S. DPP-IV-resistant, long-acting oxyntomodulin derivatives. J Pept Sci. 2011;17(4):270–80. doi:https://doi.org/10.1002/psc.1328.
   PubMed Web of Science ®Google Scholar
• Teplyakov A, Obmolova G, Malia TJ, Luo J, Muzammil S, Sweet R, Almagro JC, Gilliland GL. Structural diversity in a human antibody germline library. MAbs. 2016;8(6):1045–63. doi:https://doi.org/10.1080/19420862.2016.1190060.
   PubMed Web of Science ®Google Scholar
• Obmolova G, Teplyakov A, Malia TJ, Grygiel TLR, Sweet R, Snyder LA, Gilliland GL. Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888. Mol Immunol. 2012;51(2):227–33. doi:https://doi.org/10.1016/j.molimm.2012.03.022.
   PubMed Web of Science ®Google Scholar
• Arafat AM, Kaczmarek P, Skrzypski M, Pruszyńska-Oszmalek E, Kołodziejski P, Szczepankiewicz D, Sassek M, Wojciechowicz T, Wiedenmann B, Pfeiffer AFH. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia. 2013;56(3):588–97. doi:https://doi.org/10.1007/s00125-012-2803-y.
   PubMed Web of Science ®Google Scholar
• Habegger KM, Stemmer K, Cheng C, Muller TD, Heppner KM, Ottaway N, Holland J, Hembree JL, Smiley D, Gelfanov V. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes. 2013;62(5):1453–63. doi:https://doi.org/10.2337/db12-1116.
   PubMed Web of Science ®Google Scholar
• Biswas K, Nixey TE, Murray JK, Falsey JR, Yin L, Liu H, Gingras J, Hall BE, Herberich B, Holder JR. Engineering antibody reactivity for efficient derivatization to generate Na V 1.7 inhibitory GpTx-1 Peptide–antibody conjugates. ACS Chem Biol. 2017;12(9):2427–35. doi:https://doi.org/10.1021/acschembio.7b00542.
   PubMed Web of Science ®Google Scholar
• Kosinski JR, Hubert J, Carrington PE, Chicchi GG, Mu J, Miller C, Cao J, Bianchi E, Pessi A, SinhaRoy R. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity (Silver Spring). 2012;20(8):1566–71. doi:https://doi.org/10.1038/oby.2012.67.
   PubMed Web of Science ®Google Scholar
• Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–48. doi:https://doi.org/10.1056/NEJMoa1616011.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. doi:https://doi.org/10.1056/NEJMoa1603827.
   PubMed Web of Science ®Google Scholar
• Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, Wagenknecht LE, Pi-Sunyer FX, Kahn SE, Clark JM. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33(10):2156–63. doi:https://doi.org/10.2337/dc10-0856.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.e5. quiz e14-5. doi:https://doi.org/10.1053/j.gastro.2015.04.005.
   PubMed Web of Science ®Google Scholar
• Kang L, Camacho RC, Li W, D’Aquino K, You S, Chuo V, Weng N, Jian W. Simultaneous catabolite identification and quantitation of large therapeutic protein at the intact level by immunoaffinity capture liquid chromatography–high-resolution mass spectrometry. Anal Chem. 2017;89(11):6065–75. doi:https://doi.org/10.1021/acs.analchem.7b00674.
   PubMed Web of Science ®Google Scholar